



SYNERGIA

Updates

Zeitgeist

Fun

In This Issue

PAGE 2

The long awaited Dengue Vaccine is approved for use in Asian and LatAm markets

PAGE 3

The FDA approvals for Antipsychotic therapy

PAGE 4

Causal relationship established between Vit D deficiency and Alzheimer disease

Newer Treatment options for H Pylori infection – an update

Fixed dose combination for pediatric migraine

PAGES 5 -7

KCP – a year in events
An update on the important events that took place during 2015

PAGE 8

A report on the NSS unit of KCP and the social outreach initiatives efforts during 2015



10 Dec
2015



The spirit of the festive season was ushered in by celebrating Christmas with usual enthusiasm and pageantry at the Krupanidhi Group of Institutions. In this dazzling event, the renowned student choir of Krupanidhi Colleges performed to an enthralled audience.

The student choir was conducted and led by the Campus Director, Dr. Sam Paul and the Managing Director Ms. Neha Nagpal. The event was attended by the students and graced by the presence of Chairman, Vice Chair of KET and all the principals of the KET institutions.

Editorial



Dear all,

From this issue *Synergia* steps into its 5th year. All through these times we have seen *Synergia* taking baby strides and firmly establishing in the KCP firmament. Initially conceived as a quarterly news letter to serve the clinical pharmacy domain, *Synergia* now has expanded its scope to become a flag bearer of KCP.

Like all things go, change is the only constant. From this issue on, *Synergia* has acquired a new editorial team, consistent with its young and dynamic image. A team of young and vibrant KCPians have taken the charge of *Synergia* with me at the helm. I want to thank the previous team, for taking us here.

Synergia true to its credo will be continuing to serve the pharmacy profession and to highlight the achievements and milestones of KCP. But without you our efforts would be incomplete. Please send in your contributions and comments to our team. This will help us to set the course of synergies to come. Please let us know how you want *Synergia* to be. Looking forward to hear from you.

Rajeswari R
Editor

Lead Update



Dengue Vaccine Approved in Asian and LatAm countries

According to WHO, nearly 40 percent of the world's population (3.9 billion people) is at risk of contracting dengue. Sanofi Pasteur, the vaccines division of Sanofi, has been granted marketing approval for Dengvaxia® in the Philippines, making it the first vaccine to be licensed for the prevention of dengue in Asia.

The approval followed two years of clinical trials worldwide on more than 40,000 patients. Dengvaxia, developed over the past 20 years at a cost of 1.5 billion euros (\$1.65 billion), including manufacturing investments, awaits approval in at least 17 other countries.

India Dengvaxia, is being examined by the Indian drug regulatory agency for exemption from large-scale clinical trials on patients, the sources said. If cleared, the step may eventually pave the way for its availability via the wide government distribution system and private channels.

In India, trials for Dengvaxia were carried out in Delhi, Ludhiana, Kolkata, Pune and Bengaluru on adults between 18 to 45 years. Dr AP Dubey, director at the Maulana Azad Medical College and Lok Nayak Hospital, who was a principal investigator during the India trials, said the vaccine "after three doses was well tolerated and produced antibodies against all four dengue serotypes" in the patients.

Sanofi is yet to fix the price for Dengvaxia in India but said it will depend on whether it is made part of routine immunisation.

We would like to hear from you!

Please send your contributions, feedbacks and suggestions to: dic.krupanidhi@gmail.com/
rajeswari.emails@gmail.com


**Clinical
Update**

Newly approved anti psychotics in 2015 - a review

Antipsychotics are a class of drugs used to control psychotic symptoms in patients with psychotic disorders such as schizophrenia and delusional disorder and enables proper functioning in daily life for individual.

Two new second-generation antipsychotics were approved in 2015: Brexpiprazole (Rexulti) and cariprazine (Vraylar).

Brexpiprazole

- Oral second generation antipsychotic approved by FDA on July 13, 2015.
- D2 partial agonists ,associated with risk of akathisia

Approved for treatment of schizophrenia and as antidepressant for major depressive disorder.

Drug Interactions:

1. Strong CYP2D6 or CYP3A4 inhibitors
2. Administer half of usual dose
3. Strong/moderate CYP2D6 with Strong/moderate CYP3A4 inhibitors
4. Administer a quarter of usual dose
5. Strong CYP3A4 inducers

Double the usual dose and further adjust based on clinical response

Starting Dose: 1.5 mg/day

Recommended

Dose: 1.5-6 mg.day

Capsule: 1.5 mg,3 mg,4.5 mg

6 mg

Cariprazine

- Approved drug by FDA for treatment of manic episodes in bipolar disorder on September 17, 2015.
- Partial agonist at D2, D3 and 5-HT1A receptors and Antagonist at 5-HT2B and 5-HT2A receptors, with moderate to low affinity at H1 receptor and 5-HT2C receptors.

• Drug Interactions:

1. Metabolized by CYP3A4
2. Strong CYP3A4 inhibitors: reduce dosage by half, do not recommend use with cariprazine.

Recommended Dose: 2-4 mg/day

Tablets:

0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg

- Arjan Aryal, 5 Pharm D, Krupanidhi College of Pharmacy, Bangalore

USFDA approves Treximet: sumatriptan and naproxen sodium fixed dose combination, for pediatric migraine

U.S. Food and Drug Administration (FDA) has approved Treximet (sumatriptan and naproxen sodium) for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura. Treximet is the first approved combination prescription medicine, and the first to contain sumatriptan, for the treatment of acute migraine attacks in pediatric patients. The two medicines – sumatriptan and naproxen sodium – in combination provide more effective, sustained control of the pain and associated symptoms of migraine compared to either medicine taken alone. Approval came after the FDA's review of pivotal phase 3 safety and efficacy clinical trial, plus long-term safety and pharmacokinetic data, demonstrating that Treximet is significantly more effective than placebo in treating migraine in pediatric patients and has a favorable safety profile similar to that of Treximet for adults. Although Treximet carries a warning noting cardiovascular and gastrointestinal risks.

Dr. Sonal Dubey Sharma, Professor, Krupanidhi College of Pharmacy, Bangalore



**Rapid
Reviews**

LOW VITAMIN D LEVELS MAY INCREASE RISK OF ALZHEIMER'S

A recent study, published in *JAMA Neurology*, has confirmed that significantly low vitamin D levels reflect a decline in cognitive ability. The findings indicate that low vitamin D levels can also be responsible for brain structure abnormalities, cognitive decline and incident dementia. In the US, deficiency and insufficiency of vitamin D - also known as 25-hydroxyvitamin D - are prevalent, especially in older people. "Insufficiency" is classified as 25-OHD blood levels between 12-20 ng/mL, and "deficiency" is less than 12 ng/mL.

The National Health and Nutrition Examination Survey previously found that 42% of the general adult population were either deficient or insufficient in vitamin D, with the percentage rising to over 50% after age 65. The prevalence was even higher among Hispanic (69%) and African-American (82%) individuals.


The three main causes for low vitamin D are:

- Not eating the recommended levels of vitamin D in food - for example, when following a strict vegan diet, because most dietary sources are animal-based. Good sources include fish and fish oils, egg yolks, cheese, fortified milk and beef liver
- Limited exposure to sunlight, since the body creates vitamin D when the skin is exposed to sunlight. This can occur in northern latitudes, where people are home-bound, and in hot countries, where people avoid the sun, or in cultures where modesty requires the body to be fully covered
- Darker skin color. While the pigment melanin in darker skin offers more protection against skin cancer, it also reduces the skin's ability to make vitamin D when exposed to sunlight.



Merlin Thomas, Pharm D intern, Krupanidhi College of Pharmacy, Bangalore

HELICOBACTER PYLORI



Helicobacter pylori infections are the most common in today's scenario. The conventional drug regimens are obsolete and yet resistant now. Earlier drugs such as Proton Pump inhibitors are getting resistant now and lower efficacy is reported. Recent studies show that oral recombinant vaccine is safe and effective to be used however on the contrary triple and quadruple therapies are more effective such as Rifabutin, and tetracycline combinations. Moreover pipeline studies suggest that Nitrofurantoin, Probiotics are safe yet effective with low toxicity. Hence H. Pylori infections can be controlled based on the studies of the resistance pattern and change of the drug regimens.

Dr. Nishi Nayak, Assistant Professor, Krupanidhi College of Pharmacy, Bangalore

2015 Milestone Events @ KCP

KCP gets the coveted NAAC accreditation



KCP got the National Accreditation and Assessment Council accreditation valid for three years. This achievement affirms, KCP's Commitment to quality education and systems. Congrats to KCP faculty and students on this achievement !

Freshers Day 2015



KCP celebrated the Freshers Day, welcoming the freshers has always been a KCP tradition. The event was graced by the presence Prof B Suresh, President, PCI.

Graduation Day 2015



The Graduating Batch of 2015 was wished well during the Graduation day. Prof Ravindranath, V-C RGHUS, Karnataka was the chief guest.

Expressions - Inter college cultural fest



Expressions - an inter college cultural festival is a annual fixture in KCP's cultural calendar. More than 200 participants from colleges all over the state competed in this event.

Talents Week



KCP encourages the well rounded development of the individual. The annual Talents week gives opportunities for KCPians to showcase and win kudos for their talents .

Formation of ACPI-KSPOR Bangalore City Chapter



Krupanidhi College of Pharmacy has taken initiation to form a "Bangalore City Student's Chapter" under ACPI-KSPOR (Consortium of Association of Community Pharmacists of India & Kautilya's Society for Pharmacoeconomics and Outcome Research (ACPI-KSPOR) in Karnataka.

ACPI-KSPOR city chapters are registered bodies engaged in promotion of research, education and training in the field of Pharmacy Practice, Pharmacovigilance, Pharmacoeconomics and Outcome Research among students, faculties in collaboration with industry and regulators.

Nancy Ashok (Pharm D Intern) & Rajeswari R (Associate Professor) from Krupanidhi College of Pharmacy were unanimously selected as Bangalore City Chapter - Student President & Faculty advisor respectively.

QA Dept. Conducts GMP training for KAPL employees



The faculty of QA department of KCP led by Prof Prakash Mallya trained the employees of KAPL on Good Manufacturing Practices. Ms Kavitha AN's pioneering lecture on GMP in Kannada language was received with appreciation.

CPPA conducts Mega Symposium



The Center for Pharmaceutical Professional Advancement on 12 Dec 2015 conducted a mega symposium at KCP.

The Following Dignitaries addressed the audience.

Mr Indu Bushan - CEO, Steer Pharmaceutical Development, Dr Ajay Khopade, Senior VP Sun Pharma Advanced R&D Center, Dr Jitendra Kadam Patent Landscape analyst, Dr. Dinesh Shenoy, Director - Research, Lupin Ltd., Mr Sudhir Nayak, Head - Metabolics unit Biocon

The event was attended by KCPians and also select invitees.

The keynote addresses of the dignitaries was followed by a panel discussion on the current trends and concerns in the pharmaceutical domain.

Vice Chairperson of KET, Mrs Geetha Nagpal was present during the event.

CPPA the brainchild of Prof Prakash V Mallya has conducted 300 plus interactions in the past, inviting the crem de la crem of the pharmaceutical and healthcare industries.

GreenChem Constitutes awards for Academic Excellence



GreenChem a discovery led phytopharmaceutical company has instituted Academic Excellence awards for the best academic performance. The toppers of the graduating classes of B Pharm, M Pharm & Pharm D, will be awarded a citation and cash prize. This award is a munificent gesture from Mr Rajendran R Founder - CEO of GreenChem. We express our heartfelt thanks to our benefactor.



Placements 2015 - companies that offered placements to KCPians

The placement team of KCP this year too has created more than 100 plus career opportunities for the graduating classes of the B Pharm, M Pharm, Pharm D and D Pharm. We thank our recruiters for their trust in us.

Placement team comprises M/S Ruchi Agrawal, Deepti V, Litha working under the guidance of Prof Prakash Mallya. Kudos to KCP-Placement team!



22, 23
Aug
2015

KCP Hosts the 5th P4 National Conference



The 5th National Conference on the **Role of Clinical Pharmacists in Improving Medication Safety and Pharmacoeconomics** was organized and hosted by Krupanidhi College of Pharmacy, Bangalore & Association of Community Pharmacists of India & Kautilya Society Pharmacoeconomics Outcomes Research, Bangalore City Chapter on 22 & 23 Aug 2015

A total of 290 delegates from 5 states and 5 countries participated in this event as delegates and speaker and invitees.

The scientific session was inaugurated in the august presence of Chief Guest Dr. Raghurama Bhandary, Drug Controller, Government of Karnataka, and guests of Honor Sri Gundu Rao, President, KSPC, and Sri SG Biligiri, Director, Juggat Pharma and Dr. Ivan Salamon, Professor & EU project Manager, University of Presov, Republic of Slovakia, and was presided by Prof Suresh Nagpal, Chief Patron of this event and Mrs. Geetha Nagpal, Vice Chairperson of KET, Prof Prakash V Mallya, Director, Krupanidhi College of Pharmacy.

Principal & LOC Chairman of this event was Dr. Raman Dang. Ms Rajewari R was the convener of this national conference.

The deliberations of the scientific sessions: A total of 16 topics, out of which 7 topics in Pharmacoeconomics and 8 on medication safety and a career guidance topic in Clinical pharmacy were part of the deliberations. A galaxy of 16 renowned resource persons both national and internationally, were a part of this proceedings of this 2 day programme. A total of 56 posters were presented and evaluated during the length of this conference.



NSS Activities 2015



Not Me but You - social outreach activities and events of the NSS Unit of KCP



Date	Activity	Venue
January 28, 2015	Counseling for TB Patients in association with the Directly Observed Therapy Short-Course (DOTS) officials	Government Taluk Hospital- DOTS Center, Hoskote.
February 16, 2015	Oral hygiene and Dental screening Camp	Kasavanahalli
February 17, 2015	Self-Medication Assessment Survey	Kaikondrahalli, Kasavanahalli Public
February 18 & 19, 2015	Cleanliness Drive	Kaikondrahalli, Kasavanahalli, Junnasandra
Feb 20, 2015	Planting of saplings (150 nos.)	Median of the road - Kaikondrahalli - Sarjapura road, Bangalore
February 21, 2015	Mega medical camp- Screening of Diabetes, Hypertension, Eye checkup and cancer Screening	Doddakanahalli High School, Bangalore
April 26 – April 30, 2015	Nepal earthquake victims relief programme	Donated Rs. 5.5 Lakhs: Krupanidhi Institution- Staff, students & Public around Krupanidhi College
21 Jun 15	Nepal Earthquake –Camp- Constructed temporary shelters for homeless	Belkot, Nuwakot (District), Nepal
22 Jul 15	Sapling Plantation Programme	Gunjur Lake and Krupanidhi Garden)
10 Sep 15	Youth Pro Workshop on “Enhancing Student Quality Of Life”	Krupanidhi College of Pharmacy, Bangalore
24 Sep 15	Pharmacist your partner in Mental Health: Collage and Essay writing competition	Krupanidhi College of Pharmacy, Bangalore

Patron: Dr. Suresh Nagpal, Mrs. Geetha Nagpal, Prof. Sunil Dhamangini, Ms. Neha Nagpal, Dr. Samuel Paul Isaac
Advisory Board: Dr. M D Karvekar, Prof. Prakash V Malled, Prof. Narendra Kumar, Dr. Raman Dang, Dr. R S Thakur, Dr. Sonal Dubey, Dr. NM Mahesh, Dr. Syed Imam Rabbani

Editorial Team: Dr. Nishi Nayak, Bincy Varghese, Teena Nazeem, Akash Saxena, Dr. Vidya Alex

Joint Editor & Technical Lead: Chandramouli R

Editor: Rajeswari R